Role of the CYP2D subfamily in metabolism-dependent covalent binding of propranolol to liver microsomal protein in rats
- 16 November 1994
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 48 (10) , 1891-1898
- https://doi.org/10.1016/0006-2952(94)90587-8
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Kinetic analysis of mutual metabolic inhibition of lidocaine and propranolol in rat liver musomesBiochemical Pharmacology, 1993
- Induction of propranolol metabolism by the azo dye sudan III in ratsBiochemical Pharmacology, 1992
- Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranololBiochemical Pharmacology, 1991
- Hepatic Microsomal Propranolol Metabolism in Aging Male and Female RatsJournal of Pharmaceutical Sciences, 1991
- Propranolol oxidation by human liver microsomes‐the use of cumene hydroperoxide to probe isoenzyme specificity and regio‐ and stereoselectivity.British Journal of Clinical Pharmacology, 1990
- Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activitiesClinical Pharmacology & Therapeutics, 1989
- Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockadeClinical Pharmacology & Therapeutics, 1984
- The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.British Journal of Clinical Pharmacology, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Ring-hydroxylated propranolol: synthesis and .beta.-receptor antagonist and vasodilating activities of the seven isomersJournal of Medicinal Chemistry, 1981